Form 4: Zimmer Biomet Director Acquires Phantom Stock Units

Zimmer Biomet Holdings, Inc. Director Arthur J. Higgins acquired 280.326 phantom stock units, increasing his beneficial ownership to 35,577.223 units.

Summary

• Arthur J. Higgins, a Director at Zimmer Biomet Holdings, Inc. (ZBH), acquired 280.326 phantom stock units.
• This transaction occurred on September 30, 2025, as part of the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors.
• The conversion or exercise price of these phantom stock units is 1-for-1, with a value of $98.1 per unit.
• Following this acquisition, Mr. Higgins beneficially owns a total of 35,577.223 phantom stock units.
• The total includes 90.68 phantom stock units accrued on July 31, 2025, through the dividend reinvestment provision of the same plan.
• These units are scheduled to be settled in cash through ten annual installments, commencing within sixty days after Mr. Higgins ceases service as a Director.

Sentiment

Score: 6

Explanation: The sentiment is mildly positive as it indicates a director's continued alignment with shareholder interests through a deferred compensation plan, which is a standard and expected corporate governance practice. It does not, however, signal any extraordinary operational or financial developments.

Positives

• Director Arthur J. Higgins increased his beneficial ownership of phantom stock units, aligning his interests further with shareholders' long-term value.
• The acquisition is part of a structured deferred compensation plan, indicating a stable and pre-defined compensation arrangement for non-employee directors.

Negatives

• The phantom stock units are settled in cash upon cessation of service, rather than directly in equity, meaning no direct increase in equity ownership for the director at settlement.

Future Outlook

The filing indicates that the phantom stock units will be settled in cash in ten annual installments commencing within sixty days after the reporting person's service as a Director ceases.

Industry Context

This transaction reflects a common practice in corporate governance where non-employee directors receive a portion of their compensation in deferred equity-linked instruments, such as phantom stock units, to align their long-term interests with those of shareholders. Such plans are prevalent across various industries, including medical technology.

Comparison to Industry Standards

• Deferred compensation plans for non-employee directors, often including phantom stock units, are a standard practice in publicly traded companies, particularly within the healthcare and medical device sectors. This aligns with compensation structures seen at peers like Stryker Corporation or Medtronic plc, which also utilize equity-based or equity-linked compensation to retain and incentivize board members.
• The settlement in cash over ten annual installments post-service is a common feature designed to provide long-term retention and post-retirement benefits, similar to arrangements observed in other large-cap companies.

Stakeholder Impact

• Shareholders: The transaction demonstrates continued alignment of a director's long-term financial interests with the company's performance, potentially fostering confidence in governance.
• Employees: No direct impact mentioned.
• Customers: No direct impact mentioned.
• Suppliers: No direct impact mentioned.
• Creditors: No direct impact mentioned.

Next Steps

• Phantom stock units are to be settled in cash in ten annual installments commencing within sixty days after the end of the calendar year in which the cessation of Arthur J. Higgins' service as a Director occurs.

Key Dates

Recommendation

This Form 4 reports a routine acquisition of phantom stock units by a director as part of a deferred compensation plan. While it indicates continued alignment of director interests with shareholders, it does not represent an open market purchase or a significant new development that would fundamentally alter the investment thesis for Zimmer Biomet Holdings, Inc. Therefore, it is not a catalyst for a change in investment recommendation, and a 'hold' stance remains appropriate based solely on this filing.

Keywords

Zimmer Biomet, ZBH, Form 4, Insider Transaction, Director Compensation, Phantom Stock Units, Deferred Compensation